Want to see SE:ALZCUR full AI Analyst Report?

AlzeCure Pharma AB (ALZCUR) Price & Analysis

0 Followers

ALZCUR Stock Chart & Stats

kr2.44

kr0.16(7.05%)

At close: Mar 06 4:00 PM EST

kr2.44

kr0.16(7.05%)

Day’s Range― - ―

52-Week Rangekr1.14 - kr8.06

Previous CloseN/A

Volume72.39K

Average Volume (3M)52.87K

Market Cap

kr866.00M

Enterprise Valuekr522.18

Total Cash (Recent Filing)kr32.97M

Total Debt (Recent Filing)kr2.29M

Price to Earnings (P/E)51.4

Beta0.23

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding137,897,340

10 Day Avg. Volume28,042

30 Day Avg. Volume52,872

Financial Highlights & Ratios

PEG Ratio-1.96

Price to Book (P/B)6.11

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.35

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

CNS-focused Proprietary PipelineA focused CNS portfolio can build specialized scientific expertise and create multiple value opportunities across large unmet-need markets. The proprietary small-molecule approach may support differentiated programs if clinical data validate efficacy and safety.

Partnering-led Commercialization PathwayThe model allows AlzeCure to seek external capital, development expertise and commercial reach rather than funding every late-stage activity alone. Successful partnering could diversify future income through upfront, milestone and royalty payments.

Low Balance-sheet LeverageLimited debt reduces interest and refinancing pressure compared with highly leveraged peers, preserving flexibility while programs advance. This is a relative strength, although it does not remove the need for additional funding to cover operating losses.

Bears Say

No Commercial RevenueThe absence of revenue means the company has no established commercial funding engine and remains dependent on clinical progress, partnerships or capital markets. This increases execution risk and leaves future cash generation highly contingent on pipeline outcomes.

Persistent And Widening LossesSizable operating losses indicate that research spending is not yet producing a commercial offset. Continued losses can constrain development options, weaken negotiating leverage with partners and require sustained access to external financing.

Heavy Cash Burn And Funding DependenceSubstantial recurring cash outflows imply that existing operations cannot self-fund the pipeline. Unless spending falls or development assets generate partner income, repeated financing may be required, exposing shareholders to dilution and execution risk.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.14 and its highest was kr8.06 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr866.00M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Nov 11, 2026 which is in 74 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on Aug 26, 2026. The company reported kr0.581 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 137,897,340 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of kr0.581 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.875%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.